抗HER2治疗在转移性结直肠癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.018

Abstract

Abstract: Colorectal cancer(CRC)is the third most common cancer and the second largest cause of cancer-related deaths in the world,which seriously threatens human life and health.Despite early diagnosis and treatment,a considerable number of CRC patients have a poor prognosis due to metastasis.Research on the molecular diversity of CRC not only guides the prognosis,but it also has an important reference significance for the individualized treatment of patients.Human epidermal growth factor receptor-2(HER2)is expressed in breast cancer,gastric cancer and other malignant tumors.Anti-HER2 treatment can effectively improve the prognosis of patients with HER2-positive advanced breast cancer and gastric cancer.HER2,as an emerging biomarker of metastatic colorectal cancer(mCRC),has also attracted much attention in recent years.This article reviews the current research progress in the diagnosis and treatment of HER2-positive mCRC,with a view to providing references for clinical diagnosis and drug selection.

Key words: Metastatic colorectal cancer, Human epidermal growth factor receptor-2, Precision medicine, Targeted therapy

CLC Number:

R735.3

CHEN Su, SUI Hong. Research progress of anti-HER2 therapy in metastatic colorectal cancer[J]. Journal of Practical Oncology, 2022, 36(3): 288-292.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/288

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Siegel RL,Miller KD,Goding Sauer A,et al.Colorectal cancer statistics[J].CA Cancer J Clin,2020,70(3):145-164.
3 Li QH,Wang YZ,Tu J,et al.Anti-EGFR therapy in metastatic colorectal cancer:mechanisms and potential regimens of drug resistance[J].Gastroenterol Rep(Oxf),2020,8(3):179-191.
4 Wells A.EGF receptor[J].Int J Biochem Cell Biol,1999,31(6):637-643.
5 Schechter AL,Stern DF,Vaidyanathan L,et al.The neu oncogene:an erb-B-related gene encoding a 185,000-Mr tumour antigen[J].Nature,1984,312(5994):513-516.
6 King C,Hristova K.Direct measurements of VEGF-VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization[J].J Biol Chem,2019,294(23):9064-9075.
7 Richman SD,Southward K,Chambers P,et al.HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer:analysis of 3256 patients enrolled in the QUASAR,FOCUS and PICCOLO colorectal cancer trials[J].J Pathol,2016,238(4):562-570.
8 Ross JS,Fakih M,Ali SM,et al.Targeting HER2 in colorectal cancer:the landscape of amplification and short variant mutations in ERBB2 and ERBB3[J].Cancer,2018,124(7):1358-1373.
9 Loree JM,Bailey AM,Johnson AM,et al.Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer[J].J Natl Cancer Inst,2018,110(12):1409-1417.
10 Siena S,Sartore-Bianchi A,Marsoni S,et al.Targeting the human epidermal growth factor receptor 2(HER2)oncogene in colorectal cancer[J].Ann Oncol,2018,29(5):1108-1119.
11 Bertotti A,Migliardi G,Galimi F,et al.A molecularly annotated platform of patient-derived xenografts("xenopatients")identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J].Cancer Discov,2011,1(6):508-523.
12 Yonesaka K,Zejnullahu K,Okamoto I,et al.Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab[J].Sci Transl Med,2011,3(99):99ra86.
13 Li JL,Lin SH,Chen HQ,et al.Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis[J].BMC Clin Pathol,2019,19:3.
14 Kavuri SM,Jain N,Galimi F,et al.HER2 activating mutations are targets for colorectal cancer treatment[J].Cancer Discov,2015,5(8):832-841.
15 Sartore-Bianchi A,Trusolino L,Martino C,et al.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory,KRAS codon 12/13 wild-type,HER2-positive metastatic colorectal cancer(HERACLES):a proof-of-concept,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2016,17(6):738-746.
16 Sawada K,Nakamura Y,Yamanaka T,et al.Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer[J].Clin Colorectal Cancer,2018,17(3):198-205.
17 Pathmanathan N,Bilous AM.HER2 testing in breast cancer:an overview of current techniques and recent developments[J].Pathology,2012,44(7):587-595.
18 Wolff AC,Hammond MEH,Allison KH,et al.Human epidermal growth factor receptor 2 testing in breast cancer:American society of clinical oncology/college of American pathologists clinical practice guideline focused update[J].J Clin Oncol,2018,36(20):2105-2122.
19 El-Deiry WS,Goldberg RM,Lenz HJ,et al.The current state of molecular testing in the treatment of patients with solid tumors,2019[J].CA Cancer J Clin,2019,69(4):305-343.
20 Valtorta E,Martino C,Sartore-Bianchi A,et al.Assessment of a HER2 scoring system for colorectal cancer:results from a validation study[J].Mod Pathol,2015,28(11):1481-1491.
21 Liu F,Ren C,Jin Y,et al.Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer[J].Virchows Arch,2020,476(3):391-398.
22 Che YQ,Zhang Y,Ou KP,et al.Depth of response and early tumor shrinkage for predicting clinical outcomes in HER2-positive metastatic breast cancer treated with trastuzumab[J].Cancer Manag Res,2020,12:8527-8534.
23 Hsu A,Chudasama R,Almhanna K,et al.Targeted therapies for gastroesophageal cancers[J].Ann Transl Med,2020,8(17):1104.
24 Tosi F,Sartore-Bianchi A,Lonardi S,et al.Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer[J].Clin Colorectal Cancer,2020,19(4):256-262.
25 Hainsworth JD,Meric-Bernstam F,Swanton C,et al.Targeted therapy for advanced solid tumors on the basis of molecular profiles:results from mypathway,an open-label,phase IIa multiple basket study[J].J Clin Oncol,2018,36(6):536-542.
26 Meric-Bernstam F,Hurwitz H,Raghav KPS,et al.Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study[J].Lancet Oncol,2019,20(4):518-530.
27 Lee A.Tucatinib:first approval[J].Drugs,2020,80(10):1033-1038.
28 Lee KAP,Taylor J,Rosler R,et al.Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models[J].Mol Cancer Ther,2020,19(4):976-987.
29 Strickler JH,Zemla T,Ou FS,et al.Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer(mCRC):Initial results from the MOUNTAINEER trial[J].Ann Oncol,2019,30(suppl 5):200.
30 Greally M,Kelly CM,Cercek A.HER2:an emerging target in colorectal cancer[J].Curr Probl Cancer,2018,42(6):560-571.
31 Sartore-Bianchi A,Lonardi S,Martino C,et al.Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer:the phase II HERACLES-B trial[J].ESMO Open,2020,5(5):e000911.
32 Siena S,Di Bartolomeo M,Raghav KPS,et al.A Phase II,multicenter,open-label study of trastuzumab deruxtecan(T-DXd;DS-8201)in patients(pts)with HER2-expressing metastatic colorectal cancer(mCRC):DESTINY-CRC01[J].J Clin Oncol,2021,22(6):779-789.
33 Hausman DF,Hamilton EP,Beeram M,et al.Phase 1 study of ZW25,a bispecific anti-HER2 antibody,in patients with advanced HER2-expressing cancers[J].J Clin Oncol,2017,35(suppl 4):215.

[1]	ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma [J]. Journal of Practical Oncology, 2022, 36(3): 259-262.
[2]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[3]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[4]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[5]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[6]	YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 73-77.
[7]	SONG Jiayu, FENG Yue, WANG Zhao, ZHANG Yunyan. The latest research progress of the correlation between exosomes and gynecological malignant tumor [J]. Journal of Practical Oncology, 2020, 34(6): 571-575.
[8]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[9]	LI Guozheng, PANG Da. Progression in the treatment of HER2-positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(1): 74-78.
[10]	ZUO Zhibo, GUO Zhiqin, WANG Zhen, YANG Hongjie, WU Wanxin. Research progress of Semaphorin 3F in tumors [J]. Journal of Practical Oncology, 2020, 34(1): 88-92.
[11]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[12]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[13]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[14]	YAN Shi, HUO Mingming, PANG Hui, LI Yan, CAI Li. Effects of p53 on predictive value for efficacy of endocrine drugs in postoperative postmenopausal breast cancer patients with HR positive and HER-2 positive [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 234-213.
[15]	JI Qiao, CHEN Li, HE Yuanqiao. Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 280-284.

Research progress of anti-HER2 therapy in metastatic colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments